(S,Z)-N’-hydroxy-2-methylpiperidine-1-carboximidamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (S,Z)-N’-hydroxy-2-methylpiperidine-1-carboximidamide
• 英文别名: (2S)-N'-hydroxy-2-methylpiperidine-1-carboximidamide
• 化学式: C₇H₁₅N₃O
• 分子量: 157.216
• InChiKey: JRDOYXRJHWDOPL-LURJTMIESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  61.8
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (S,Z)-N’-hydroxy-2-methylpiperidine-1-carboximidamide 在 盐酸 、 N,N-二异丙基乙胺 、 N,N'-二环己基碳二亚胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 16.0h， 生成 1-methyl-N-((S)-1-(3-((S)-2-methylpiperidin-l-yl)-1,2,4-oxadiazol- 5-yl)ethyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide
  参考文献：
  名称：

  [EN] KCNT1 INHIBITORS AND METHODS OF USE
  [FR] INHIBITEURS DE KCNT1 ET MÉTHODES D'UTILISATION

  摘要：

  Disclosed herein are compounds and compositions useful for preventing and/or treating a neurological disorder, a disorder associated with excessive neuronal excitability, or a disorder associated with a gain-of-function mutation in a gene (e.g., KCNT1). Methods of treating a neurological disorder, a disorder associated with excessive neuronal excitability, or disorder associated with a gain-of-function mutation in a gene such as KCNT1 are also provided herein.

  公开号：

  WO2022231872A1
• 作为产物：
  描述：

  (S)-2-methylpiperidine-1-carbonitrile 在 盐酸羟胺 、 三乙胺 作用下， 以 乙醇 为溶剂， 以72 %的产率得到(S,Z)-N’-hydroxy-2-methylpiperidine-1-carboximidamide
  参考文献：
  名称：

  [EN] KCNT1 INHIBITORS AND METHODS OF USE
  [FR] INHIBITEURS DE KCNT1 ET MÉTHODES D'UTILISATION

  摘要：

  Disclosed herein are compounds and compositions useful for preventing and/or treating a neurological disorder, a disorder associated with excessive neuronal excitability, or a disorder associated with a gain-of-function mutation in a gene (e.g., KCNT1). Methods of treating a neurological disorder, a disorder associated with excessive neuronal excitability, or disorder associated with a gain-of-function mutation in a gene such as KCNT1 are also provided herein.

  公开号：

  WO2022231872A1

文献信息

• [EN] KCNT1 INHIBITORS AND METHODS OF USE<br/>[FR] INHIBITEURS DE KCNT1 ET MÉTHODES D'UTILISATION
  申请人：[en]PRAXIS PRECISION MEDICINES, INC.

  公开号：WO2022231872A1

  公开（公告）日：2022-11-03

  Disclosed herein are compounds and compositions useful for preventing and/or treating a neurological disorder, a disorder associated with excessive neuronal excitability, or a disorder associated with a gain-of-function mutation in a gene (e.g., KCNT1). Methods of treating a neurological disorder, a disorder associated with excessive neuronal excitability, or disorder associated with a gain-of-function mutation in a gene such as KCNT1 are also provided herein.